New Feature Coming Soon, Stay Tuned!
Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
The Company as of 2021 is now in process of seeking a merger or acquisition candidate and working to bring the Company current. Effective October 9, 2017 the PSA Agreement with Canteck Pharma, inc. was rescinded do inability to proceed with the license for Mexico that previously had focused on its immunotherapeutic based technology specific to Cancer indication.
OTC
After-hours 0.00$
0.00 (-100.00%)
Relative Strenght
Volume Buzz
220%
Earning Acce
No
Dist 52w H.
0%